JACKSON CENTER, Pa.--(BUSINESS WIRE)--Premier Biomedical, Inc. (OTC-BB: BIEI) has announced the successful outcome of a Proof of Concept Test performed by the University of Texas at El Paso (UTEP). This experiment targeted a specified Interleukin, implicated in the development of Cancer, for removal from a heterogeneous mixture. This test was completed successfully within minutes at the Picogram level (one trillionth of a gram).
